Product Information
IVERMECTIN 1% CREAM is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $2.7461 per GM under NDC 45802010284. Its NADAC has been published 134 times since Mar 13, 2024.
FDA first approved this application on Apr 13, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10 mg/g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802010284
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
IVERMECTINApproval Type
Generic (ANDA)
FDA Application
ANDA210225FDA Approved
4/13/2020
TE Code
AB
On Market Since
1/8/2024
Pharmacological Classes
Price Statistics
The NADAC for IVERMECTIN 1% CREAM has been published 134 times since Mar 13, 2024, and over the history we have for it it has declined 30.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.7461 per GM |
|---|---|
| All-time high | $3.9203 (Mar 13, 2024) |
| All-time low | $2.5224 (Jul 17, 2024) |
| 52-week high | $3.4257 |
| 52-week low | $2.7461 |
| Median price | $3.2025 |
| Average price | $3.1903 |
| Largest weekly change | +37.5% (Aug 21, 2024) |
| Weeks tracked | 134 |
| Tracking since | Mar 13, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ivermectin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antiparasitic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IVERMECTIN 1% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for IVERMECTIN 1% CREAM, manufactured by Padagis Israel Pharmaceuticals Ltd, is $2.7461 per GM (NDC 45802010284), effective Sep 30, 2026.
How has the price of IVERMECTIN 1% CREAM changed over time?
Over the history we have for it, the NADAC for IVERMECTIN 1% CREAM has declined 30.0%. It has been tracked across 134 weekly CMS publications since Mar 13, 2024.
What are the highest and lowest recorded NADAC prices for IVERMECTIN 1% CREAM?
Since Mar 13, 2024, the NADAC for IVERMECTIN 1% CREAM has ranged from a low of $2.5224 (Jul 17, 2024) to a high of $3.9203 (Mar 13, 2024), with a median of $3.2025 per GM.
Are there cheaper alternatives to IVERMECTIN 1% CREAM?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as IVERMECTIN 1% CREAM in a comparable dosage form, but none are currently priced below it.
Who manufactures IVERMECTIN 1% CREAM?
IVERMECTIN 1% CREAM (NDC 45802010284) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.